newsfilter
← Latest News
Business Wire·

Cyclo Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Achievements

– Quarter marked by launch of Phase 2b study of Trappsol® Cyclo™ for the treatment of early Alzheimer's Disease (AD) with patient enrollment and site activation now underway – Building momentum with ongoing